Skip to content


  • Oral presentation
  • Open Access

Current aspects and future trends of computer-aided rescaffolding

  • 1,
  • 1 and
  • 1
Journal of Cheminformatics20102 (Suppl 1) :O19

  • Published:


  • High Throughput Screening
  • Chemical Entity
  • Chemical Matter
  • Chemical Space
  • Development Cost

The competitive pressure in pharmaceutical industry is reflected by longer development times and increasing development costs yielding less new chemical entities. In particular, identification of suitable lead compounds is one of the key challenges in early drug discovery. Next to well established techniques like high throughput screening (HTS) and virtual screening computer-aided rescaffolding has become an important approach in detecting novel chemical structures [1, 2].

The development of New Chemical Entities (NCEs) requires the exploration of novel landscapes in chemical space. Rescaffolding is in particular important in lead identification but also in lead optimization. If a lead series cannot be optimized in multidimensional space, scaffold-rescuing is often perceived as back-up strategy to transfer hitherto available SAR into a new scaffold.

With a binding site or a pharmacophore in hand often de novo design methods are applied to identify novel chemical matter. However, de novo design differs from rescaffolding in that the goal of the first is primarily to generate new molecules in chemical space while the latter aims to design new scaffolds under constraints: high similarity in the desired property space and novelty in scaffold space. This allows jumping out of the known region of chemical space towards new regions of chemistry resulting in molecules with similar properties and activities but with novel frameworks.

This talk will focus on ligand-based rescaffolding by taking into account only the topology of reference molecules. Several descriptors have been successfully applied for rescaffolding purposes, e.g. CATS (including CATS3D), Feature Trees (cf. ReCore), Topomers, Gaussian shape (cf. ROCS, BROOD) and others. In fragment-based rescaffolding new molecules are assembled from small (sub-) molecular fragments or building blocks often by applying pseudo-chemical rules in their recombination (e.g., RECAP). The use of fragments reduces the sampling rate of chemical space and provides access to synthesizable new compounds. This will be exemplified by two rescaffolding examples taking into account 2D as well as 3D descriptors.

Authors’ Affiliations

CAS Drug Design, Sanofi-Aventis Deutschland GmbH, Building G 878, 65926 Frankfurt am Main, Germany


  1. Krueger BA, Dietrich A, Baringhaus K-H, Schneider G: Scaffold-Hopping Potential of Fragment-Based De Novo Design: The Chances and Limits of Variation. Combinatorial Chemistry & High Throughput Screening. 2009, 12 (4): 383-396. 10.2174/138620709788167971.View ArticleGoogle Scholar
  2. Mauser H, Guba W: Recent developments in de novo design and scaffold hopping. Current Opinion in Drug Discovery & Development. 2008, 11 (3): 365-374.Google Scholar


© Karl-Heinz et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.